Cargando…
Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer
BACKGROUND: Neoadjuvant chemotherapy (NAC) has been expanded to hormone receptor (HR) positive breast cancer (BC) patients with operable disease, to increase the likelihood of breast-conserving surgery. Genomic profiling at baseline would reveal NAC response relevant genomic features and signaling p...
Autores principales: | Dong, Menghao, Shan, Benjie, Han, Xinghua, Zhao, Xiaotian, Wang, Fufeng, Zhu, Liuqing, Ou, Qiuxiang, Ma, Xiaopeng, Pan, Yueyin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036956/ https://www.ncbi.nlm.nih.gov/pubmed/35480699 http://dx.doi.org/10.3389/fonc.2021.784985 |
Ejemplares similares
-
Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
por: Dong, Jie, et al.
Publicado: (2021) -
Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
por: Zhou, Qiong, et al.
Publicado: (2021) -
Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI
por: Lu, Nannan, et al.
Publicado: (2021) -
An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
por: Fu, Changfang, et al.
Publicado: (2021) -
Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patients
por: Chen, Jian, et al.
Publicado: (2022)